Advertisement

Topics

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

17:59 EST 14 Nov 2017 | News-Medical.net

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Original Article: AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...